Thursday, March 26, 2015

Daniel Hoffman

Pharma as a fading power hitter

Wednesday, June 12, 2013, 6:00 AM
Approximately half the drugs now in clinical development involve an approach known as targeted therapy. Last week's posting discussed some of the problems associated with that strategy. These include increasing the risks of drug development, price gouging, fostering a blind-leading-the-blind phenomenon... Read more

Pharma needs an R&D strategy

Thursday, June 6, 2013, 10:08 AM
Recently a knowledgeable pharma veteran lamented the fact that the industry has not widely adopted what he considers a particularly useful approach to drug development. One company "had it right," he wrote, "when their research model was to study particular pathways and find drugs to affect various... Read more

Organize health care as if it was war

Wednesday, May 29, 2013, 6:00 AM
Does the private control of drug development and health care in general bestow better health and prosperity on Americans? For people in the C-suites, their bluestocking shareholders and some others, it undoubtedly does. For most Americans, it doesn't appear to work so well. Earlier this year the... Read more

Can Pharma handle pricing for value in this country?

Tuesday, May 21, 2013, 10:05 AM
All sectors in the health care business face major turning points within the next three years. This means the pharmaceutical industry and other manufacturers, together with providers such as physicians and hospitals, will operate in a different environment by the end of this decade. The important... Read more

Pharmas made less money but bought their own stock

Monday, May 13, 2013, 9:27 AM
Did anyone in Big Pharma post improved results for the first quarter? Pfizer, Merck, Bristol-Myers Squibb, AstraZeneca, GlaxoSmithKline, Sanofi and Novartis (the last two in their pharmaceutical operations) all generated lower sales this past quarter, compared to the same period last year. Some companies... Read more

Feds again go after Pharma, with a couple of twists

Tuesday, May 7, 2013, 10:50 AM
Last week the US Justice Department filed suit against Novartis that essentially accuses the company of bribing physicians with lavish dinners, trips and speaking fees so they would prescribe the company's drugs. The suit alleges, "In many instances Novartis made payments to doctors for purported... Read more

Pharma's informative week that was

Wednesday, April 24, 2013, 9:48 AM
Some weeks it seems as if random events can inadvertently array themselves to reveal the pharmaceutical industry's fundamentals the way a stormy sea provides a glimpse of the ocean floor. This was just such a week. In one story that appeared within the last few days, a large consultancy reinforced... Read more

What’s the purpose of GSK’s Open Office?

Thursday, April 18, 2013, 6:00 AM
GlaxoSmithKline claims the "open plan" for its new office building near the naval shipyard creates "flexible and transparent spaces" that will encourage face-to-face collaboration, thereby reducing the amount of time wasted by email communication. According to the company, the altered work pattern... Read more

The un-free market for prescription drugs

Friday, April 12, 2013, 9:38 AM
To no one's surprise a large, multinational study published this month concluded that the per capita price for branded drugs in the US is as much as double what other advanced countries pay. The researchers from the London School of Economics and Johns Hopkins University looked at US prices for branded... Read more

When the market on Pharma stocks contradicts fundamentals

Friday, April 5, 2013, 7:00 AM
Hardly a day goes by without the stock prices of one or more Big Pharma companies reaching a 52-week high. Of the nine Big Cap pharmas covered by Sanford Bernstein, they rate six as Outperform (i.e., Buy) and three as Market-Perform (amounting to Hold). Also this week Citigroup reported that in... Read more
About this blog

Check Up covers regional health news and a wide array of healthcare topics from pharmaceutical happenings to patient safety. Read about some of our bloggers here.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Michael R. Cohen, R.Ph. President, Institute for Safe Medication Practices
Daniel R. Hoffman, Ph.D. President, Pharmaceutical Business Research Associates
Hooman Noorchashm, M.D., Ph.D. Cardiothoracic surgeon in the Philadelphia area
Amy J. Reed, M.D., Ph.D. Anesthesiologist and Surgical Intensivist in the Philadelphia Area
Latest Health Videos
Also on
Stay Connected